Literature DB >> 22094632

Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia.

Nicholas Wood1, Vicky Sheppeard, Patrick Cashman, Pamela Palasanthiran, Margot Casacelli, Kathryn Cannings, Peter McIntyre.   

Abstract

In August 2010, the United States Advisory Committee on Immunization Practices recommended that the 2010-2011 CSL seasonal vaccine (Afluria) not be administered to children 6 months to 8 years of age because of the risk of febrile convulsion after immunization. This study reports a low rate (6%-7%) of fever after immunization with 2 non-CSL brands of 2011 seasonal influenza vaccine in Australian children <5 years of age. These data are reassuring for parents and healthcare workers regarding 2011 influenza vaccination in the northern hemisphere.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22094632     DOI: 10.1097/INF.0b013e31823d5303

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.

Authors:  Hazel J Clothier; Nigel W Crawford; Melissa Russell; Heath Kelly; Jim P Buttery
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

2.  Influenza hospitalizations in Australian children.

Authors:  J Li-Kim-Moy; J K Yin; C C Blyth; A Kesson; R Booy; A C Cheng; K Macartney
Journal:  Epidemiol Infect       Date:  2017-02-06       Impact factor: 4.434

Review 3.  Participant-centred active surveillance of adverse events following immunisation: a narrative review.

Authors:  Patrick Cashman; Kristine Macartney; Gulam Khandaker; Catherine King; Michael Gold; David N Durrheim
Journal:  Int Health       Date:  2017-05-01       Impact factor: 2.473

4.  Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study.

Authors:  Peter Jacoby; Catherine Glover; Chloe Damon; Parveen Fathima; Alexis Pillsbury; David Durrheim; Michael S Gold; Alan Leeb; Tom Snelling
Journal:  BMJ Open       Date:  2020-03-01       Impact factor: 2.692

Review 5.  The manufacturing process should remain the focus for severe febrile reactions in children administered an Australian inactivated influenza vaccine during 2010.

Authors:  Jean Li-Kim-Moy; Robert Booy
Journal:  Influenza Other Respir Viruses       Date:  2016-01       Impact factor: 4.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.